Aeglea BioTherapeutics Secures $12,000,000 New Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=1b381279-ed11-478a-8b38-9f52f4f285c0 - Date
1/9/2014 - Company Name
Aeglea BioTherapeutics - Mailing Address
815-A Brazos St. Austin, TX 78701 - Company Description
Aeglea BioTherapeutics is a Texas based start up developing two drugs invented at UT Austin, novel engineered human enzymes that degrade the amino acids L-methionine (L-Met), or L- arginine (LArg) in the circulation. These drugs target the dependence of different tumors on L- Met or L-Arg for survival. - Website
Undisclosed
- Transaction Type
Venture Equity - Transaction Amount
$12,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
During the next 15 to 18 months, the company plans to begin manufacturing of its lead molecule and complete the prep work to begin the first phase of clinical trials. - M&A Terms
- Venture Investor
KBI Biopharma
